PRESS RELEASE Gedea Biotech Receives US Patent for Preventing Preterm Birth
Lund, Sweden, March 27, 2025 Gedea Biotech announced today that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application covering the active ingredient in the company’s first product, pHyph, to prevent preterm birth (premature delivery) in pregnant women…
Gedea Biotech Reports Significant Results in Study for the Treatment of Bacterial Vaginosis
PRESS RELEASE Lund, Sweden, March 12, 2025 Gedea Biotech has completed a clinical study, the NEFERTITI-2 study, for the treatment of bacterial vaginosis, showing significantly better treatment outcomes with the company's vaginal tablet pHyph compared to the control group. This result forms the…
